Market closedNon-fractional
Landec/LFCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Landec
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Ticker
LFCR
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Chaska, United States
Employees
459
Website
www.lifecore.com
Landec Metrics
BasicAdvanced
$151M
Market cap
-
P/E ratio
-$3.41
EPS
0.98
Beta
-
Dividend rate
Price and volume
Market cap
$151M
Beta
0.98
Financial strength
Current ratio
2.389
Quick ratio
1.225
Long term debt to equity
500.667
Total debt to equity
505.939
Interest coverage (TTM)
-1.12%
Management effectiveness
Return on assets (TTM)
-4.67%
Return on equity (TTM)
-104.52%
Valuation
Price to revenue (TTM)
1.419
Price to book
-80.15
Price to tangible book (TTM)
-7.41
Price to free cash flow (TTM)
-2.653
Growth
Revenue change (TTM)
-7.19%
Earnings per share change (TTM)
-16.20%
3-year revenue growth
-13.59%
3-year earnings per share growth
36.40%
What the Analysts think about Landec
Analyst Ratings
Majority rating from 1 analysts.
Landec Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$26M
-7.61%
Net income
-$36M
-11.47%
Profit margin
-139.21%
-4.18%
Landec Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.32
-$0.24
-$0.22
-$0.89
-
Expected
-$0.14
-$0.04
-$0.13
-$0.38
-$0.26
Surprise
137.04%
500.00%
69.23%
137.33%
-
Landec News
AllArticlesVideos
The Schall Law Firm Motivates Investors With Losses To Initiate Interaction As It Commences Inquiry Into Lifecore Biomedical Inc
Accesswire·16 hours ago
The Schall Law Firm Urges Investors With Losses To Initiate Communication As It Begins Inquiry Into Lifecore Biomedical Inc
Accesswire·3 days ago
The Schall Law Firm Encourages Investors With Losses To Begin Contact As It Starts Investigation Into Lifecore Biomedical Inc
Accesswire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Landec stock?
Landec (LFCR) has a market cap of $151M as of July 06, 2024.
What is the P/E ratio for Landec stock?
The price to earnings (P/E) ratio for Landec (LFCR) stock is 0 as of July 06, 2024.
Does Landec stock pay dividends?
No, Landec (LFCR) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Landec dividend payment date?
Landec (LFCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Landec?
Landec (LFCR) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Landec stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.